FDA 483 OBSERVATION · #13 OF 1,923 MOST-CITED
Investigations of discrepancies, failures
FDA cited this observation 977 times across 817 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
A batch or component failed to meet specification, or an unexplained discrepancy occurred, and the firm either did not investigate, investigated inadequately, or did not extend the investigation to other batches and products that could have been affected.
Why FDA writes it — This is the pharmaceutical quality unit’s core obligation. An out-of-specification result or unexplained discrepancy is a signal that something in the process is not controlled; a thorough, documented investigation is how the firm protects every other batch that shared the same cause.
- Investigate every unexplained discrepancy and every batch or component failure to meet specification, whether or not the batch was already distributed — and record a written conclusion with a scientific rationale.
- Do not invalidate an OOS result without a documented, investigated laboratory or manufacturing cause; “retest into compliance” without root cause is a classic citation.
- Extend the investigation to other batches and other products that may have been associated with the same failure, and document that scope decision.
- Drive the conclusion into CAPA so the root cause is corrected, not just the batch dispositioned.
- Investigations that stop at the laboratory and default to “analyst error” without confronting a possible manufacturing root cause.
- No scope step: the failing batch is dispositioned but sibling batches sharing the same lot, line, or component are never assessed.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 4.4× the rate of the average FDA-cited firm (33.8% vs 7.8%), across 817 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →